floxuridine has been researched along with Neutropenia in 5 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Advanced prostate cancer, which is one of the most common cancers, usually progresses to hormone-refractory prostate cancer (HRPC)." | 2.73 | Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. ( Honda, J; Kai, N; Kikuchi, K; Kikukawa, H; Kuwahara, T; Matsumoto, K; Nakanishi, J; Takahashi, W; Ueda, S; Wada, Y, 2008) |
| "Gemcitabine alone was given in cycle 1 as a 24-h, 2-h or 1-h i." | 2.71 | A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. ( Chen, A; Grem, JL; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Rowedder, A; Takimoto, CH; Xu, Y, 2003) |
| "Six Japanese cancer patients treated with gemcitabine plus cisplatin were examined." | 2.71 | Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. ( Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 1 |
| Gu, Y | 1 |
| Zhao, M | 1 |
| Yuan, Y | 1 |
| Wang, F | 1 |
| Wang, Z | 1 |
| Li, W | 1 |
| Luo, H | 1 |
| Chen, C | 1 |
| Chen, G | 1 |
| Ding, P | 1 |
| Wu, X | 1 |
| Lu, Z | 1 |
| Pan, Z | 1 |
| Xu, R | 1 |
| He, Y | 1 |
| Wan, D | 1 |
| Li, Y | 1 |
| Grem, JL | 1 |
| Quinn, MG | 1 |
| Keith, B | 1 |
| Monahan, BP | 1 |
| Hamilton, JM | 1 |
| Xu, Y | 1 |
| Harold, N | 1 |
| Nguyen, D | 1 |
| Takimoto, CH | 1 |
| Rowedder, A | 1 |
| Pang, J | 1 |
| Morrison, G | 1 |
| Chen, A | 1 |
| Yonemori, K | 1 |
| Ueno, H | 1 |
| Okusaka, T | 1 |
| Yamamoto, N | 1 |
| Ikeda, M | 1 |
| Saijo, N | 1 |
| Yoshida, T | 1 |
| Ishii, H | 1 |
| Furuse, J | 1 |
| Sugiyama, E | 1 |
| Kim, SR | 1 |
| Kikura-Hanajiri, R | 1 |
| Hasegawa, R | 1 |
| Saito, Y | 1 |
| Ozawa, S | 1 |
| Kaniwa, N | 1 |
| Sawada, J | 1 |
| Wada, Y | 1 |
| Kikuchi, K | 1 |
| Takahashi, W | 1 |
| Honda, J | 1 |
| Nakanishi, J | 1 |
| Matsumoto, K | 1 |
| Kuwahara, T | 1 |
| Kai, N | 1 |
| Kikukawa, H | 1 |
| Ueda, S | 1 |
| Takiuchi, H | 1 |
| Goto, M | 1 |
| Imamura, H | 1 |
| Furukawa, H | 1 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Kimura, Y | 1 |
| Ishida, H | 1 |
| Fujitani, K | 1 |
| Narahara, H | 1 |
| Shimokawa, T | 1 |
5 trials available for floxuridine and Neutropenia
| Article | Year |
|---|---|
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dr | 2003 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cis | 2005 |
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Pro | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |